SMSbiotech Welcomes New Board of Advisor Member Dr. Jason P. Kirkness
Read
SMSbiotech is developing cutting-edge adult stem cell technology that aims at providing safe, affordable, and ethically grounded regenerative medicine.
SMSbiotech is developing cutting-edge adult stem cell technology that aims to provide safe, effective, affordable, and ethically grounded regenerative medicine.
SMSbiotech has been at the forefront of developing cutting-edge adult stem cell technology dedicated to providing safe, effective, affordable, and ethically grounded regenerative medicine.
Leveraging our patented technology (6 received, 10 pending), we bio-manufacture human Small Mobile Stem Cells and essential proteins derived from these cells, including matrisomal and other extracellular matrix proteins.
Through extensive development, we have established large, industrial-scale production capabilities for SMS cells and their byproducts, ensuring widespread availability for medical applications.
Our proprietary techniques enable the isolation and indefinite growth of native adult SMS cells, laying the foundation for groundbreaking regenerative therapies.
As true stem cells, SMS cells exhibit strong interactions with key regenerative cells (Mesenchymal Stem Cells, Endothelial Cells, Alveolar Progenitor Cells, Chondrocytes, and Fibroblast), stimulating growth and triggering gene expression changes without transformation or manipulation.
Novel in-vitro functional assay systems meticulously test SMS cell bio-manufacturing quality, guaranteeing in-vivo potency at both cellular and molecular levels. SMS cells have resilient properties that help maintain the quality of the cells.
The remarkable physical and chemical resilience of SMS cells allows them to serve tissues and organs effectively even under stressful, diseased conditions, opening new avenues for drug administration, rational logistics, and simple storage (4°C for 3 weeks).
SMS cells produce ample proteins known for their regenerative effects on human cells and tissues. The extracellular matrix derived from SMS cells demonstrates exceptional blood vessel inducement in-vitro and in-vivo. Large visible vessels can be formed in-vitro.
Rigorous studies utilizing animal models showcase the exceptional therapeutic potential of SMS cells, effectively regenerating damaged tissues in the skin and lungs.
Extensive safety assessments, including large-scale administration to various tissues and animal species, confirm the absence of adverse effects and tumorigenicity as expected from adult stem cells.
Stimulation of parenchymal cells and progenitor stem cell proliferation, coupled with tissue vascularization and extracellular matrix production, forms the foundation for rapid and effective tissue healing in diverse organs.
Our in-vitro and in-vivo research highlights the potential of SMS cells for addressing Chronic Obstructive Pulmonary Disease (COPD), a severe, degenerative lung condition lacking effective treatment that affects +400 million people worldwide.
Our technology grants patients access to high-quality, immuno-tolerant, and affordable human (allogeneic, off-the-shelf) therapeutic cells, expanding treatment options and addressing unmet needs that affect hundreds of millions worldwide.
Beyond cells, our technology yields critical therapeutic proteins at an industrial scale, facilitating in vivo tissue regeneration and in vitro tissue reconstruction.
SMSbiotech's robust technology paves the way for cost-effective methods in organ repair, tissue and vascular regeneration, and scaffold and tissue engineering.
SMS cells can proliferate extensively without losing functional potency, retaining their ability to differentiate into other cells, interact with key regenerative cells, and produce critical regenerative factors.
SMS cells have been extensively proliferated and rigorously tested in vitro and in vivo, using multiple animal species, to demonstrate consistent safety and the absence of toxicity and tumorigenicity.
SMS cells are not genetically manipulated, further enhancing their safety profile compared to genetically engineered counterparts.
Unlike embryonic and genetically engineered cells, SMS cells are adult stem cells derived from adult human tissues. This characteristic ensures that transferring SMS cells to human tissue does not expose it to embryonic state cells, providing a safer option for cell therapy.
SMS cells are isolated from regular blood and return to their natural habitat when injected into the bloodstream. This characteristic distinguishes them from adult Mesenchymal Stem cells, offering unique advantages.
SMS cells stimulate mesenchymal stem cell proliferation, potentially inducing beneficial regenerative effects of MSCs endogenously.
Unlike Mesenchymal stem cells that primarily target immune cells, SMS cells target multiple different cells that have direct significance to tissue regeneration.
SMS cells possess very few to no histocompatibility proteins, reducing the likelihood of inducing significant immune reactions, in contrast to MSCs.
The smaller size of SMS cells reduces the risk of clogging capillaries and getting stuck in the lungs, which can be a concern with Mesenchymal cells.
SMS cells are sturdier and more robust, providing practical benefits in their handling and application.